TCTR20231024002已完成3 期
Effects of Topical Corticosteroids, Topical Corticosteroids Under Occlusion, and Topical Brimonidine on the Prevention of Postinflammatory Hyperpigmentation After Q-Switched 532-nm Nd:YAG Laser Treatment of Solar Lentigines
Faculty of Medicine, Srinakharinwirot University0 个研究点目标入组 36 人开始时间: 2023年10月24日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
Topical clobetasol, topical clobetasol under occlusion, and topical brimonidine were not found to be significantly effective in reducing the incidence of PIH and intensity of PIH after laser treatment of solar lentigines on the forearms. However, topical clobetasol and topical clobetasol under occlusion might be effective in reducing posttreatment erythema.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Male or female subjects above 18 years of age
- •2. Subjects who have at least 8 solar lentigines on the forearms (diagnosed clinically or dermoscopically by a dermatologist). The lesions should be located on 4 different areas of the forearms; including left upper forearm, left lower forearm, right upper forearm, and right lower forearm; and there should be at least 2 lesions in each area.
- •3. Subjects who are willing to attend the project and sign informed consent form
排除标准
- •1. Subjects who have active inflammatory diseases or infections at the site of treatment
- •2. Subjects who have photosensitive skin conditions
- •3. Subjects with a history of hypertrophic scars or keloids
- •4. Subjects with a history of skin malignancy
- •5. Subjects who received topical retinoids, hydroquinone, chemical peeling, or other topical whitening agents at the site of treatment within a period of 1 months prior to treatment
- •6. Subjects who received oral retinoids within 6 months prior to treatment
- •7. Subjects who underwent non-ablative laser therapy at the site of treatment within a period of 3 months prior to treatment
- •8. Subjects who underwent ablative laser therapy at the site of treatment within a period of 6 months prior to treatment
- •9. Subjects who are allergic to topical analgesics, topical corticosteroids, topical brimonidine, petrolatum jelly, or other inactive ingredients of the medication such as propylene glycol, paraffin, sorbitan sesquioleate, carbomer, methylparahydroxybenzoate, phenoxyethanol, glycerol, titanium dioxide, and sodium hydroxide
- •10. Subjects who have conditions that should avoid using topical brimonidine
- •11. Subjects who have coagulation disorders
- •12. Subjects who are pregnant or lactating women
- •13. Subjects who are likely to have impaired wound healing such as smokers or patients with poorly controlled diabetes mellitus
研究者
相似试验
招募中
2 期
corticosteroids in chronic subdural hematomachronic SubDural hematoma.Nontraumatic chronic subdural hemorrhageI62.03IRCT20200911048685N1Ahvaz University of Medical Sciences30
尚未招募
Unknown
A study on usage of topical corticosteroids in conditions related to the skiCTRI/2023/12/060667Dr Reddys Laboratories Ltd
已完成
不适用
Chronic paronychia - a form of hand dermatitisCTRI/2016/07/007107Jawaharlal Institute of Postgraduate Medical Education Research70
已完成
2 期
The effect of photodynamic therapy on oral lichen planusoral lichen planus.Lichen planusIRCT201606208585N2Vice Chancellor for research of Shiraz University of Medical Science22
招募中
4 期
Corticosteroid eye-drops for bacterial keratitisBacterial keratitisEye - Diseases / disorders of the eyeInfection - Other infectious diseasesACTRN12612000055808niversity of Auckland144